| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Careers Employment > Career Planning - Winning the Performance Review Game |
|
Digg It - Career Planning - Winning the Performance Review Game
Q. My performance review was disappointing, although I’ve had two promotions in the last four yea According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product rs. My boss said I needed to work on showing more leadership skills when I’m working on a team. W ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in en I try to pin him down for a discussion, he brushes me aside. A. As you move up the ladder, yo lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ’ll be expected to work on your own, with less
and less feedback and direction. A lack of feed here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ack can be a sign that you’re trusted and respected. You’re expected
to read between the lines d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro nd interpret unwritten signals. Start with these three questions: Q1. What is your company’s cu ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ture around performance reviews? In some cultures, you’re expected to take a negative review in easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi stride. Responding
will be viewed as defensive and insecure behavior. Other cultures value disc nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ssion
and at least the appearance of openness. Q2. What signals are you sending? Your boss ne and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ds to know that you’re willing to talk tough. You can say something
like, “Don’t worry about h ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi rting my feelings. Just share with me anytime, even if it’s
something small.” Then act on your ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a romise. You might say, “I’m happy with my review – just trying to learn. Can you give me some dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod specific examples of situations where I could have demonstrated more
leadership? And examples o cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin what you’re looking for?” Q3. What’s the unwritten message? Your boss may be absolutely deligh tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ted with your performance, but the rules (formal
or informal) require him to include negative a t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ong with positive feedback. So he
threw in some comments about leadership, which don’t amount t ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust much. The key is to take your performance review in context. If you’re receiving tangible rec y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products gnition – increased responsibility, invitations to key meetings, attention from
major players – . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de you’ll appear insecure if you worry about your performance review.
But if you’re getting warni elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip g signals – missed meetings, weaker assignments – you
need to understand what’s really going on tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Discussing The Pains of Change with Clients How to Use Flyers to Expand Your Business Jumping on the Brandwagon - How to Give Your City a Motto Makeover in 10 Easy Steps
|